Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
This study is ongoing, but not recruiting participants.
Study NCT00268918 Information provided by Dana-Farber Cancer Institute
First Received: December 21, 2005 Last Updated: October 30, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Endometrial Neoplasms
Fallopian Tube Neoplasms
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Breast Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Skin Diseases
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
Docetaxel
PTK787
Additional drug interventions recognized in this trial
Vatalanib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Back to top of Main Content
